Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.52 |
| ▸ | FLT3 | P36888 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105419 | 1.00 | EGFR (0.52) | EGFRERBB2FLT3GAAKDM4E | |
| SCHEMBL1105373 | 0.88 | FLT3 (0.62) | EGFRERBB2FLT3 | |
| SCHEMBL4737722 | 0.88 | FLT3 (0.62) | EGFRERBB2FLT3 | |
| SCHEMBL1096176 | 0.86 | ADK (0.47) | FLT3GAAKDM4EMEN1KMT2A | |
| SCHEMBL1105278 | 0.83 | EGFR (0.66) | EGFRERBB2FLT3 | |
| SCHEMBL5005537 | 0.83 | EGFR (0.66) | EGFRERBB2FLT3 | |
| SCHEMBL1095355 | 0.76 | EGFR (0.71) | EGFRERBB2 | |
| SCHEMBL1105378 | 0.76 | EGFR (0.71) | EGFRERBB2 | |
| SCHEMBL1095766 | 0.74 | EGFR (0.65) | EGFRERBB2 | |
| SCHEMBL1096859 | 0.74 | EGFR (0.75) | EGFRERBB2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007081630-A2 | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | claimed |
| US-8278446-B2 | reacting 4-amino-6-chloro-pyrimidine-5-carbaldehyde with 4-benzyloxy-3-chloro-phenylamine in an aqueous solvent and a catalytic amount of hydrochloric acid, to providw 4-amino-6-(4-benzyloxy-3-chloro-phenylamino)-pyrimidine-5-carbaldehyde, then oximination with (2-morpholin-4-yl-ethyl)-hydroxylamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| US-20080249304-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-09 | — | — | US | disclosed |
| WO-2007081630-A2 | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249304-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | DHPS, DPYD, DCPS | EGFR 1036/4885ERBB2 301/4885FLT3 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.